<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520972</url>
  </required_header>
  <id_info>
    <org_study_id>PB119201</org_study_id>
    <nct_id>NCT03520972</nct_id>
  </id_info>
  <brief_title>Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-weekly Subcutaneous Doses of PB-119 in Drug-naïve Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PegBio Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PegBio Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel dose cohort,
      multiple dose study to evaluate the efficacy, safety, and tolerability of different doses of
      PB-119 in drug-naïve subjects with T2DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be assessed for eligibility over a 2-week screening period prior to a 2-week
      run-in period and a 12-week double-blind treatment period,4-week follow up period. The
      eligible patients will be randomized to 1 of 3 dose cohorts (A, B, or C). Each patient will
      subsequently be randomized within the designated cohort to active drug or placebo at a 3:1
      active drug:placebo ratio.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">September 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of HbA1c from baseline value to end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving HbA1c &lt;7%</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of patients achieving HbA1c &lt;7% at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving HbA1c ≤6.5%</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of patients achieving HbA1c ≤6.5% at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>2, 4, and 8 weeks</time_frame>
    <description>Changes of HbA1c from baseline value at Weeks 2, 4, and 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Changes of FPG from baseline value at Weeks 2, 4, 8, and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-h PPG</measure>
    <time_frame>4, 8, and 12 weeks</time_frame>
    <description>Changes of 2-h PPG from baseline value at Weeks 4, 8, and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin</measure>
    <time_frame>4, 8, and 12 weeks</time_frame>
    <description>Changes of insulin from baseline value at Weeks 4, 8, and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>4, 8, and 12 weeks</time_frame>
    <description>Changes of C-peptide from baseline value at Weeks 4, 8, and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-monitoring of blood glucose (SMBG)</measure>
    <time_frame>4, 8, and 12 weeks</time_frame>
    <description>Changes of mean profile and mean increments from baseline value of the 7-point SMBG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>BMI</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Changes of BMI from baseline value at Weeks 2, 4, 8, and 12.</description>
  </other_outcome>
  <other_outcome>
    <measure>waist and hip circumferences and waist-to-hip ratio</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of waist and hip circumferences and waist-to-hip ratio from baseline value at end of treatment(waist and hip circumferences will be used to calculate waist-to-hip ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>blood pressure(both systolic and diastolic)</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Changes of blood pressure from baseline value at Weeks 2, 4, 8, and 12.</description>
  </other_outcome>
  <other_outcome>
    <measure>blood lipid</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Changes of blood lipid from baseline value at Weeks 2, 4, 8, and 12</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PB-119 75ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 150ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 200ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo injection subcutaneously injected once-weekly for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB-119 75ug</intervention_name>
    <description>60 eligible patients will be included in this group</description>
    <arm_group_label>PB-119 75ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB-119 150ug</intervention_name>
    <description>60 eligible patients will be included in this group</description>
    <arm_group_label>PB-119 150ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB-119 200ug</intervention_name>
    <description>60 eligible patients will be included in this group</description>
    <arm_group_label>PB-119 200ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>60 eligible patients will be included in this group</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and/or females between the ages of ≥18 and ≤70 years at Screening

          2. Patients in whom T2DM has been diagnosed according to 1999 WHOT2DM diagnostic criteria

          3. HbA1c ≥7.5% and ≤11% at Screening and at Week -1

          4. Body mass index (BMI) ≥18.5 and ≤35.0 kg/m2 at Screening

        Exclusion Criteria:

          1. Female who is pregnant, intends to become pregnant or breast-feeding or is of
             child-bearing potential and not using adequate contraception methods throughout the
             trial

          2. Treatment with any glucose lowing agent(s) within 3 months prior to screening.An
             exception is short-term treatment (no longer than 7 days in total) with insulin in
             connection with inter-current illness

          3. Calcitonin ≥50 ng/L at screening

          4. Patients with a personal or family history of medullary thyroid carcinoma or multiple
             endocrine neoplasia, type 2

          5. Fasting triglyceride ≥500 mg/dL at Screening, or patients with a history of lipid
             disorders taking unstable treatment dosage (eg, statins) within 3 months prior to
             screening

          6. Any acute or chronic condition that, in the opinion of the Investigator, would limit
             the patient's ability to complete and/or participate in this trial

          7. Blood amylase or lipase &gt;3x ULN, history of acute or chronic pancreatitis, or history
             of symptomatic gallbladder disease at Screening

          8. Serum creatinine ≥1.5 mg/dL (male patients) or ≥1.4 mg/dL (female patients), or
             estimated glomerular filtration rate (eGFR) &lt;45 mL/min/1.73 m2 at Screening

          9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2x upper limit of
             normal (ULN) at Screening and pre-randomization

         10. Severe cardiovascular diseases occurring within 6 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

